Effect of venlafaxine on the pharmacokinetics of terfenadine

Psychopharmacology Bulletin

Volumn 34, Issue 3, 1998, Pages 383-389

  Amchin, Jess ^a,b   Zarycranski, William ^a   Taylor, Karen P ^a   Albano, Dominick ^a   Klockowski, Patricia M ^c  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Oneida Research Services Inc   (United States)

Author keywords

Interaction; P450 isoenzyme CYP3A4; Pharmacokinetics; Terfenadine; Venlafaxine

Indexed keywords

CYTOCHROME P450; TERFENADINE; VENLAFAXINE;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; TERFENADINE;

EID: 0031766614     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Amchin, J; Zarycranski, W; and Taylor, K. Evidence that venlafaxine does not inhibit CYP1A2 as measured in vivo by the metabolism of caffeine. Clin. Pharmacol. Therapeut. 61(2):179, 1997.
2. Amchin, JD; Ereshefsky, L; and Zarycranski, WM. "Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan, a CYP2D6 marker." Presented at the 1996 Annual Meeting of the American Psychiatric Association, New York, NY, May 7, 1996.
3. Amchin, JD, and Zarycranski, WM. Effect of venlafaxine on the pharmacokinetics of alprazolam (abstract). Psychopharmacol. Bull. 32(3):410, 1996.
4. American Society of Health-System Pharmacists. American Hospital Formulary Service 97 Drug Information. Bethesda, MD: ASHSP, 1997. pp. 30-36.
5. Babe, KS, and Serafin, WE. Histamine, bradykinin, and their antagonists. In: Harman, JG, and Limbird, LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996. pp. 581-600.
6. Ball, SE; Ahern, D; Scatina, J; and Kao, J. Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism. Comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br. J. Clin. Pharmacol. 43:619-626, 1997.
7. Cohen, LJ. Rational drug use in the treatment of depression. Pharmacotherapy 17(1):45-61, 1997.
8. Ereshefsky, L. Drug-drug interactions involving antidepressants: Focus on venlafaxine. J. Clin. Psychopharmacol. 16(Suppl. 2):37S-53S, 1996.
9. Fogelman, S; Schmider, J; Greenblatt, DJ; and Shader, RI. Metabolism of venlafaxine: The role of P450 isoforms (abstract). J. Clin. Pharmacol. 35:936, 1995.
10. Garteiz, DA; Hook, RH; Walker, BJ; and Okerholm, RA. Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittel-Forschung 32:1185-1190, 1982.
11. Holliday, SM, and Benfield, P. Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 49(2):280-294, 1995.
12. Honig, PK; Wortham, DC; Zamani, K; Conner, DP; Mullin, JC; and Cantilena, LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-1518, 1993.
13. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23(4):349-359, 1993.
14. Jusko, WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans, WE; Schentag, JJ; Jusko, WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3d ed. Vancouver: Applied Therapeutics, 1992:2-1-2-43.
15. Klamerus, KJ; Maloney, K; Rudolph, RL; Sisenwine, SF; Jusko, WJ; and Chiang, ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J. Clin. Pharmacol. 32:716-724, 1992.
16. Ling, K-HJ; Leeson, GA; Burmaster, SD; Hook, RH; Reith, MK; and Cheng, LK. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab. Disp. 23:631-636, 1995.
17. McTavish, D; Goa, KL; and Ferrill, M. Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs 39(4):552-574, 1990.
18. Muth, EA; Moyer, JA; Haskins, JT; Andree, TH; and Husbands, GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23:191-199, 1991.
19. Nemeroff, CB; DeVane, CL; and Pollock, BG. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153:311-320, 1996.
20. Otton, SV; Ball, SE; Cheung, SW; Inaba, T; Rudolph, RL; and Sellers, EM. Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br. J. Clin. Pharmacol. 41:149-156, 1996.
21. Richelson, E. Pharmacology of antidepressants - Characteristics of the ideal drug. Mayo Clin. Proc. 69:1069-1081, 1994.
22. SAS Institute, Inc. SAS/STAT User's Guide: Version 6, 4th ed, Vol 1 and 2. Cary, NC: SAS Institute, 1990.
23. Scott, MA; Shelton, PS; and Gattis, W. Therapeutic options for treating major depression, and the role of venlafaxine. Pharmacotherapy 16(3):352-365, 1996.
24. Troy, SM; Lucki, I; Peirgies, AA; Parker, V; Klockowski, PM; and Chiang, ST. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J. Clin. Pharmacol 35:410-419, 1995a.
25. Troy, SM; Parker, VD; Fruncillo, RJ; and Chiang, ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J. Clin. Pharmacol 35:404-409, 1995b.
26. Troy, SM; Schultz, RW; Parker, VD; Chiang, ST; and Blum, RA. The effect of renal disease on the disposition of venlafaxine. Clin. Pharmacol Ther. 56:14-21, 1994.
27. von Moltke, LL; Greenblatt, DJ; Duan, SX; Harmatz, JS; Wright, CE; and Shader, RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J. Clin. Psychopharmacol 16:104-112, 1996.
28. von Moltke, LL; Greenblatt, DJ; Schmider, J; Harmatz, JS; and Shader, RI. Metabolism of drugs by cytochrome P450 3A isoforms: Implications for drug interactions in psychopharmacology. Clin. Pharmacokinet. 29(Suppl. 1):33-44, 1995.
29. Wiklander, B; Danjou, P; Rolan, P; Tamin, SK; and Toon, S. Evaluation of the potential pharmacokinetic interaction of venlafaxine and carbamazepine (abstract). Eur. Neuropsychopharmacol 5:310-311, 1995.
30. Yonkers, KA; Kando, JC; Cole, JO; and Blumenthal, S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am. J. Psychiatry 149:587-595, 1992.